Core Viewpoint - Fu'an Pharmaceutical (300194) announced on September 26 that it will disclose all R&D projects entering the registration process in its periodic reports and will provide interim disclosures for significant progress [1] Group 1 - The company will disclose relevant investments and matters that need to be reported through designated media [1]